€12m · Other round · Healthtech · Hanover, Germany
Hanover-based seragy has secured €12m in mixed debt, equity and public funding backed by Commerzbank, Mittelständische Beteiligungsgesellschaft Niedersachsen and the State of Lower Saxony. The company did not disclose how the financing is split. It will use the capital to expand its laboratory and analytical capacity, grow its Hanover team and extend collaborations with pharmaceutical and biotechnology companies.
Making protein aggregation measurable
seragy develops biomarkers for proteopathies, diseases including Alzheimer's, Parkinson's and ALS in which proteins aggregate abnormally. Conventional seed-amplification assays can identify whether a disease-associated protein signal is present, but they often produce a binary result. seragy's SeRAS platform is designed to turn those signals into quantitative molecular fingerprints that distinguish aggregation patterns and track biological changes.
For drug developers, that could make a biomarker useful across more of the development process. A test that identifies molecular subtypes and measures change may help partners choose research strategies, group patients more precisely and evaluate whether a therapy is affecting its intended biology. Those uses remain dependent on validation, reproducibility and performance in real patient samples; the financing therefore supports both scientific development and the operational capacity to run more partner work.
The platform combines seeding-based biochemistry with high-sensitivity optics, automated data analysis, software algorithms and micromechanical components around the MetisOne Analyzer. seragy holding owns the intellectual property, while its wholly owned analytics subsidiary carries out services and projects for partners. That structure points to a commercial model built around licensed technology and specialist biomarker work rather than developing a single therapy of its own.
From assay development to partner delivery
Founded in 2022 as Prosperodes, the company is led by protein-aggregation researchers Christiane Ritter and Thorsten Lührs alongside business and finance executive Arne Ungruh. An earlier Michael J. Fox Foundation award supports work on a quantitative Parkinson's assay. The foundation's programme targets a specific limitation in current alpha-synuclein seed-amplification tests: highly sensitive detection exists, but binary results cannot measure disease progression or treatment response.
The €12m package gives seragy room to move from funded assay development toward broader delivery for pharma and biotech partners. Mixed financing also matters: equity, borrowing and public support can fund different parts of the scale-up, but the undisclosed split leaves the company's dilution, debt-service burden and effective runway unclear. The practical milestone will be whether added laboratory throughput and international collaborations produce repeatable biomarker programmes that partners use in preclinical and clinical decisions.
